EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Relief Therapeutics Holding's Enterprise Value is CHF6.82 Mil.
Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-90.79 Mil. Therefore, Relief Therapeutics Holding's EV-to-EBIT for today is -0.08.
The historical rank and industry rank for Relief Therapeutics Holding's EV-to-EBIT or its related term are showing as below:
XSWX:RLF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -4323.82 Med: -1.81 Max: 0.05
Current: -0.07
During the past 13 years, the highest EV-to-EBIT of Relief Therapeutics Holding was 0.05. The lowest was -4323.82. And the median was -1.81.
XSWX:RLF's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.05
vs XSWX:RLF: -0.07
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Relief Therapeutics Holding's Enterprise Value for the quarter that ended in Jun. 2023 was CHF24.11 Mil.
Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-90.79 Mil. Relief Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -376.59%.
Relief Therapeutics Holding EV-to-EBIT Historical Data
The historical data trend for Relief Therapeutics Holding's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Relief Therapeutics Holding's EV-to-EBIT
For the Biotechnology subindustry, Relief Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's EV-to-EBIT falls into.
Relief Therapeutics Holding's current Enterprise Value is CHF6.82 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-90.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Relief Therapeutics Holding's Enterprise Value for the quarter that ended in Jun. 2023 was CHF24.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was CHF-90.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Relief Therapeutics Holding's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Relief Therapeutics Holding (XSWX:RLF) Business Description
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:RLF has been successfully added to your 